Drug news
Health Canada approves Prochymal (Osiris Therapeutics) for Graft-v-Host Disease in children
Canadian health regulators have approved Prochymal, from Osiris Therapeutics, for acute Graft-v-Host Disease in children who are not responding to steroid therapy, making it the first stem cell drug to be approved for a systemic disease anywhere in the world. Prochymal was authorized under Health Canada's Notice of Compliance with conditions (NOC/c) pathway, which provides access to therapeutic products that address unmet medical conditions and which have demonstrated a favorable risk/benefit profile in clinical trials. Under the NOC/c pathway, the sponsor must agree to carry out confirmatory clinical testing.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins